← 產業報告目錄

CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-05-14頁數 267報告編號 BT6746

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025, at a significant CAGR of 11.2%. The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines. “Products dominated the CRISPR market, by offering, in 2024.” Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services. Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth. “The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period.” The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology. “Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024.” Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share. “North America accounted for the largest share of the CRISPR market in 2024.” The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France. In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (70%) and Demand Side (30%) • By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%) • By Region: North America (35%), Europe (30%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) The prominent players operating in the CRISPR market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), Lonza Group (Switzerland), Danaher Corporation (US), Revvity, Inc. (US), Hera BioLabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US), among others. Research Coverage: The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)]. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market. Key Benefits of Buying the Report: The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market. The report provides insights into the following pointers: • Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases and expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the market. • Product Development/Innovation: In-depth analysis of emerging technologies in CRISPR, R&D activities, and new product launches in the CRISPR market. • Market Development: The report provides detailed information about profitable markets and analyzes the market conditions across various regions. • Market Diversification: Comprehensive information about new products, unexplored regions, recent updates, and investments in the CRISPR market. • Competitive Assessment: Comprehensive evaluation of market shares, growth strategies, and product & service offerings of leading companies such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).
目錄 Table of Contents
1 INTRODUCTION 24 1.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.3 STUDY SCOPE 25 1.3.1 MARKETS COVERED & REGIONAL SCOPE 25 1.3.2 INCLUSIONS & EXCLUSIONS 26 1.3.3 YEARS CONSIDERED 26 1.3.4 CURRENCY CONSIDERED 27 1.4 STAKEHOLDERS 27 1.5 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 2.1.1 SECONDARY DATA 29 2.1.2 PRIMARY RESEARCH 30 2.2 MARKET SIZE ESTIMATION 32 2.2.1 GLOBAL MARKET ESTIMATION 32 2.2.1.1 Insights From Primary Experts 35 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 35 2.3 MARKET GROWTH RATE PROJECTION 37 2.4 DATA TRIANGULATION 38 2.5 RESEARCH ASSUMPTIONS 39 2.6 RESEARCH LIMITATIONS 40 2.7 RISK ANALYSIS 41 3 EXECUTIVE SUMMARY 42 4 PREMIUM INSIGHTS 45 4.1 CRISPR MARKET OVERVIEW 45 4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024) 46 4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030 46 5 MARKET OVERVIEW 47 5.1 INTRODUCTION 47 5.2 MARKET DYNAMICS 47 5.2.1 DRIVERS 48 5.2.1.1 Growing demand for CRISPR-based gene therapies 48 5.2.1.2 Advancements in CRISPR technology 49 5.2.1.3 Growing government and private investments and funding for CRISPR technology 50 5.2.2 RESTRAINTS 51 5.2.2.1 Technical challenges associated with CRISPR technology 51 5.2.3 OPPORTUNITIES 51 5.2.3.1 Development of new vaccines and treatments for genetic diseases 51 5.2.3.2 Expanding industrial and agricultural applications of CRISPR 52 5.2.4 CHALLENGES 52 5.2.4.1 Regulatory hurdles for CRISPR advancements 52 5.2.5 TECHNOLOGY ANALYSIS 53 5.2.5.1 Key technologies 53 5.2.5.1.1 CRISPR-Cas systems 53 5.2.5.1.2 gRNA design & optimization 54 5.2.5.1.3 High-throughput CRISPR screening 54 5.2.5.2 Complementary technologies 54 5.2.5.2.1 Synthetic biology 54 5.2.5.2.2 Single-cell genomics 55 5.2.5.2.3 Next-generation sequencing 55 5.2.5.3 Adjacent technologies 55 5.2.5.3.1 Stem cell engineering 55 5.2.5.3.2 Synthetic DNA & gene synthesis 56 5.2.5.3.3 Microfluidics 56 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 57 5.4 SUPPLY CHAIN ANALYSIS 57 5.5 VALUE CHAIN ANALYSIS 59 5.6 ECOSYSTEM ANALYSIS 60 5.7 PORTER’S FIVE FORCES ANALYSIS 62 5.7.1 THREAT OF NEW ENTRANTS 63 5.7.2 THREAT OF SUBSTITUTES 63 5.7.3 BARGAINING POWER OF BUYERS 63 5.7.4 BARGAINING POWER OF SUPPLIERS 64 5.7.5 INTENSITY OF COMPETITIVE RIVALRY 64 5.8 REGULATORY ANALYSIS 65 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 5.8.2 REGULATORY FRAMEWORK 70 5.8.2.1 North America 70 5.8.2.1.1 US 70 5.8.2.1.2 Canada 70 5.8.2.2 Europe 70 5.8.2.2.1 Germany 70 5.8.2.2.2 UK 70 5.8.2.2.3 France 71 5.8.2.3 Asia Pacific 71 5.8.2.3.1 Japan 71 5.8.2.3.2 China 71 5.8.2.4 Latin America 71 5.8.2.4.1 Brazil 71 5.8.2.5 Middle East & Africa 72 5.8.2.5.1 GCC Countries 72 5.8.2.5.2 South Africa 72 5.9 PRICING ANALYSIS 72 5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024) 73 5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022–2024 73 5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES 74 5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024 75 5.10 PATENT ANALYSIS 76 5.11 KEY CONFERENCES & EVENTS, 2025–2026 78 5.12 KEY STAKEHOLDERS & BUYING CRITERIA 79 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 5.12.2 CRISPR MARKET: BUYING CRITERIA 80 5.13 INVESTMENT & FUNDING SCENARIO 81 5.14 IMPACT OF AI ON CRISPR MARKET 81 5.15 TRADE ANALYSIS 83 5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019–2023 83 5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019–2023 84 5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET 84 5.15.3.1 Introduction 84 5.15.3.2 Key tariff rates 85 5.15.3.3 Price impact analysis 86 5.15.3.4 Key Impact on various regions 87 5.15.3.4.1 US 87 5.15.3.4.2 Europe 87 5.15.3.4.3 Asia Pacific 88 5.15.3.4.4 Rest of the World 88 5.15.3.5 End-use industry impact 88 5.15.3.5.1 Pharmaceutical & biotech companies 89 5.15.3.5.2 Contract research organizations (CROs) 89 5.15.3.5.3 Academic & research institutes 89   6 CRISPR MARKET, BY OFFERING 90 6.1 INTRODUCTION 91 6.2 PRODUCTS 91 6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 91 6.3 SERVICES 93 6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET 93 7 CRISPR PRODUCTS MARKET, BY TYPE 96 7.1 INTRODUCTION 97 7.2 CRISPR KITS & ENZYMES 97 7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD 97 7.3 CRISPR LIBRARIES 99 7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH 99 7.4 OTHER PRODUCTS 101 8 CRISPR PRODUCTS MARKET, BY END USER 104 8.1 INTRODUCTION 105 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105 8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET 105 8.3 ACADEMIC & RESEARCH INSTITUTES 108 8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET 108 8.4 OTHER END USERS 110 9 CRISPR MARKET, BY SERVICE 112 9.1 INTRODUCTION 113 9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT 113 9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth 113 9.1.2 SCREENING & VALIDATION 115 9.1.2.1 Rapid advancements in CRISPR technology to drive growth 115 9.2 OTHER SERVICES 118 10 CRISPR SERVICES MARKET, BY END USER 120 10.1 INTRODUCTION 121 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 121 10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 121 10.3 ACADEMIC & RESEARCH INSTITUTES 123 10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET 123 10.4 OTHER END USERS 126 11 CRISPR MARKET, BY APPLICATION 128 11.1 INTRODUCTION 129 11.2 DRUG DISCOVERY & DEVELOPMENT 129 11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 129 11.3 AGRICULTURE 132 11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH 132 11.4 OTHER APPLICATIONS 134 12 CRISPR MARKET, BY REGION 136 12.1 INTRODUCTION 137 12.2 NORTH AMERICA 137 12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 138 12.2.2 US 141 12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth 141 12.2.3 CANADA 144 12.2.3.1 Increasing demand for gene-editing technologies to boost growth 144 12.3 EUROPE 146 12.3.1 MACROECONOMIC OUTLOOK OF EUROPE 146 12.3.2 GERMANY 150 12.3.2.1 Rapidly increasing biotechnology sector to support growth 150 12.3.3 UK 152 12.3.3.1 Significant government investments in genomics research to propel growth 152 12.3.4 FRANCE 155 12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth 155 12.3.5 ITALY 157 12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth 157 12.3.6 SPAIN 160 12.3.6.1 Increasing demand for precision medicine to drive growth 160 12.3.7 REST OF EUROPE 162 12.4 ASIA PACIFIC 164 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 164 12.4.2 CHINA 169 12.4.2.1 Increasing investments in R&D to drive growth 169 12.4.3 JAPAN 171 12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth 171 12.4.4 INDIA 174 12.4.4.1 Increasing prevalence of genetic disorders to support growth 174 12.4.5 REST OF ASIA PACIFIC 176 12.5 LATIN AMERICA 179 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 179 12.5.2 BRAZIL 182 12.5.2.1 Growing adoption of genome technologies to propel growth 182 12.5.3 REST OF LATIN AMERICA 184 12.6 MIDDLE EAST & AFRICA 186 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 186 13 COMPETITIVE LANDSCAPE 190 13.1 INTRODUCTION 190 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 190 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET 191 13.3 REVENUE ANALYSIS, 2020−2024 192 13.4 MARKET SHARE ANALYSIS, 2024 192 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 194 13.5.1 STARS 194 13.5.2 EMERGING LEADERS 194 13.5.3 PERVASIVE PLAYERS 195 13.5.4 PARTICIPANTS 195 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 196 13.5.5.1 Company footprint 196 13.5.5.2 Region footprint 197 13.5.5.3 Product footprint 197 13.5.5.4 Service footprint 198 13.5.5.5 Application footprint 199 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 199 13.6.1 PROGRESSIVE COMPANIES 199 13.6.2 RESPONSIVE COMPANIES 199 13.6.3 DYNAMIC COMPANIES 200 13.6.4 STARTING BLOCKS 200 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 201 13.6.5.1 Detailed list of key startups/SMEs 201 13.6.5.2 Competitive benchmarking of key startups/SMEs 202 13.7 COMPETITIVE SCENARIO 203 13.7.1 PRODUCT LAUNCHES & APPROVALS 203 13.7.2 DEALS 204 13.7.3 EXPANSIONS 205 13.8 COMPANY VALUATION & FINANCIAL METRICS 206 13.9 BRAND/PRODUCT COMPARISON 207   14 COMPANY PROFILES 208 14.1 KEY PLAYERS 208 14.1.1 THERMO FISHER SCIENTIFIC INC. 208 14.1.1.1 Business overview 208 14.1.1.2 Products/Services offered 209 14.1.1.3 Recent developments 211 14.1.1.3.1 Product/Service launches 211 14.1.1.3.2 Deals 211 14.1.1.3.3 Expansions 212 14.1.1.4 MnM view 212 14.1.1.4.1 Key strengths 212 14.1.1.4.2 Strategic choices 213 14.1.1.4.3 Weaknesses & competitive threats 213 14.1.2 MERCK KGAA 214 14.1.2.1 Business overview 214 14.1.2.2 Products/Services offered 215 14.1.2.3 Recent developments 216 14.1.2.3.1 Deals 216 14.1.2.4 MnM view 217 14.1.2.4.1 Key strengths 217 14.1.2.4.2 Strategic choices 217 14.1.2.4.3 Weaknesses & competitive threats 217 14.1.3 AGILENT TECHNOLOGIES, INC. 218 14.1.3.1 Business overview 218 14.1.3.2 Products/Services offered 219 14.1.3.3 Recent developments 220 14.1.3.3.1 Deals 220 14.1.3.3.2 Expansions 221 14.1.3.4 MnM view 221 14.1.3.4.1 Key strengths 221 14.1.3.4.2 Strategic choices 221 14.1.3.4.3 Weaknesses & competitive threats 221 14.1.4 GENSCRIPT 222 14.1.4.1 Business overview 222 14.1.4.2 Products/Services offered 223 14.1.4.3 Recent developments 225 14.1.4.3.1 Product/service approvals/launches 225 14.1.4.3.2 Deals 225 14.1.4.3.3 Expansions 226 14.1.5 REVVITY 227 14.1.5.1 Business overview 227 14.1.5.2 Products/Services offered 228 14.1.5.3 Recent developments 230 14.1.5.3.1 Deals 230 14.1.6 LONZA 231 14.1.6.1 Business overview 231 14.1.6.2 Products/Services offered 232 14.1.6.3 Recent developments 233 14.1.6.3.1 Deals 233 14.1.7 DANAHER CORPORATION 234 14.1.7.1 Business overview 234 14.1.7.2 Products/Services offered 235 14.1.7.3 Recent developments 236 14.1.7.3.1 Deals 236 14.1.8 TAKARA BIO INC. 237 14.1.8.1 Business overview 237 14.1.8.2 Products/Services offered 238 14.1.8.3 Recent developments 239 14.1.8.3.1 Deals 239 14.1.9 CREATIVE BIOGENE 240 14.1.9.1 Business overview 240 14.1.9.2 Products/Services offered 240 14.1.9.3 Recent developments 241 14.1.9.3.1 Product/service approvals/launches 241 14.1.10 FUJIAN SUNYBIOTECH CO., LTD. 242 14.1.10.1 Business overview 242 14.1.10.2 Products/Services offered 242 14.1.11 EDITCO 243 14.1.11.1 Business overview 243 14.1.11.2 Products/Services offered 243 14.1.11.3 Recent financials 244 14.1.11.3.1 Deals 244 14.1.12 CARIBOU BIOSCIENCES, INC. 245 14.1.12.1 Business overview 245 14.1.12.2 Products/Services offered 246 14.1.12.3 Recent developments 246 14.1.12.3.1 Deals 246 14.1.13 HERA BIOLABS 247 14.1.13.1 Business overview 247 14.1.13.2 Products/Services offered 247 14.1.14 ORIGENE TECHNOLOGIES, INC. 248 14.1.14.1 Business overview 248 14.1.14.2 Products/Services offered 248   14.1.15 CELLECTA, INC. 249 14.1.15.1 Business overview 249 14.1.15.2 Products/Services offered 249 14.2 OTHER PLAYERS 251 14.2.1 MAMMOTH BIOSCIENCES, INC. 251 14.2.2 APPLIED STEMCELL 251 14.2.3 NEW ENGLAND BIOLABS 252 14.2.4 TOOLGEN, INC. 253 14.2.5 GENECOPOEIA, INC. 254 14.2.6 TWIST BIOSCIENCE 255 14.2.7 SYNTHEGO 256 14.2.8 EGENESIS 257 14.2.9 INSCRIPTA, INC. 257 14.2.10 PRECISION BIOSCIENCES 258 15 APPENDIX 259 15.1 DISCUSSION GUIDE 259 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262 15.3 CUSTOMIZATION OPTIONS 264 15.4 RELATED REPORTS 265 15.5 AUTHOR DETAILS 266
圖表清單 List of Tables & Figures
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 38 TABLE 2 CRISPR MARKET: RISK ANALYSIS 41 TABLE 3 CRISPR MARKET: IMPACT ANALYSIS 48 TABLE 4 CRISPR MARKET: ROLE OF COMPANIES IN ECOSYSTEM 61 TABLE 5 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS 63 TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66 TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 11 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022–2024 73 TABLE 12 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024 (USD) 75 TABLE 13 CRISPR MARKET: INNOVATIONS AND PATENT REGISTRATIONS 77 TABLE 14 CRISPR MARKET: KEY CONFERENCES & EVENTS, 2025–2026 78 TABLE 15 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 80 TABLE 16 IMPORT DATA FOR KITS & REAGENTS, BY REGION, 2019–2023 (USD) 83 TABLE 17 EXPORT DATA FOR KITS & REAGENTS, BY REGION, 2019–2023 (USD) 84 TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES 85 TABLE 19 KEY TARIFFS ON PHARMACEUTICAL PRODUCTS 86 TABLE 20 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 87 TABLE 21 CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 91 TABLE 22 CRISPR PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 92 TABLE 23 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 92 TABLE 24 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 92 TABLE 25 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 26 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 27 CRISPR SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 94 TABLE 28 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 29 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 30 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 31 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 32 CRISPR PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 97 TABLE 33 CRISPR KITS & ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 34 NORTH AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 35 EUROPE: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 36 ASIA PACIFIC: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 37 LATIN AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 38 CRISPR LIBRARIES MARKET, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 39 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 40 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 41 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 42 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 43 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 44 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 45 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 46 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 47 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 48 CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 105 TABLE 49 CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 50 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 51 EUROPE: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 52 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 53 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 54 CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 55 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 56 EUROPE: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 57 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 58 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 59 CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 60 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 61 EUROPE: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 62 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 63 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 64 CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 113 TABLE 65 CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 66 NORTH AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 67 EUROPE: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 68 ASIA PACIFIC: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 69 LATIN AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 70 CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 71 NORTH AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 72 EUROPE: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 73 ASIA PACIFIC: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 74 LATIN AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 75 OTHER CRISPR SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 76 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 77 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 78 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 79 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 80 CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 121 TABLE 81 CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 82 NORTH AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 83 EUROPE: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 84 ASIA PACIFIC: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 85 LATIN AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 86 CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 87 NORTH AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 88 EUROPE: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 89 ASIA PACIFIC: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 90 LATIN AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 91 CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 92 NORTH AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 93 EUROPE: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 94 ASIA PACIFIC: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 95 LATIN AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 96 CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 129 TABLE 97 CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 98 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 99 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 100 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 101 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 102 CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 103 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 104 EUROPE: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 105 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 106 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 107 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 108 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 109 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 110 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 111 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 112 CRISPR MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 113 NORTH AMERICA: KEY MACROINDICATORS 138 TABLE 114 NORTH AMERICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 139 TABLE 115 NORTH AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 140 TABLE 116 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 140 TABLE 117 NORTH AMERICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 140 TABLE 118 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 141 TABLE 119 NORTH AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 141 TABLE 120 US: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 142 TABLE 121 US: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 142 TABLE 122 US: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 142 TABLE 123 US: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 143 TABLE 124 US: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 143 TABLE 125 US: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 143 TABLE 126 CANADA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 144 TABLE 127 CANADA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 144 TABLE 128 CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 145 TABLE 129 CANADA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 145 TABLE 130 CANADA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 145 TABLE 131 CANADA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 146 TABLE 132 EUROPE: KEY MACROINDICATORS 147 TABLE 133 EUROPE: CRISPR MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 134 EUROPE: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 148 TABLE 135 EUROPE: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 148 TABLE 136 EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 149 TABLE 137 EUROPE: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 149 TABLE 138 EUROPE: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 149 TABLE 139 EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 150 TABLE 140 GERMANY: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 150 TABLE 141 GERMANY: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 151 TABLE 142 GERMANY: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 151 TABLE 143 GERMANY: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 151 TABLE 144 GERMANY: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 152 TABLE 145 GERMANY: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 152 TABLE 146 UK: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 153 TABLE 147 UK: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 153 TABLE 148 UK: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 153 TABLE 149 UK: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 154 TABLE 150 UK: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 154 TABLE 151 UK: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 154 TABLE 152 FRANCE: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 155 TABLE 153 FRANCE: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 155 TABLE 154 FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 156 TABLE 155 FRANCE: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 156 TABLE 156 FRANCE: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 156 TABLE 157 FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 157 TABLE 158 ITALY: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 158 TABLE 159 ITALY: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 158 TABLE 160 ITALY: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 161 ITALY: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 159 TABLE 162 ITALY: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 159 TABLE 163 ITALY: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 159 TABLE 164 SPAIN: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 160 TABLE 165 SPAIN: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 160 TABLE 166 SPAIN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 161 TABLE 167 SPAIN: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 161 TABLE 168 SPAIN: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 161 TABLE 169 SPAIN: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 162 TABLE 170 REST OF EUROPE: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 162 TABLE 171 REST OF EUROPE: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 163 TABLE 172 REST OF EUROPE: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 163 TABLE 173 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 163 TABLE 174 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 164 TABLE 175 REST OF EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 164 TABLE 176 ASIA PACIFIC: KEY MACRO INDICATORS 165 TABLE 177 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 178 ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 167 TABLE 179 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 167 TABLE 180 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 167 TABLE 181 ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 168 TABLE 182 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 168 TABLE 183 ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 184 CHINA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 169 TABLE 185 CHINA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 170 TABLE 186 CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 170 TABLE 187 CHINA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 170 TABLE 188 CHINA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 171 TABLE 189 CHINA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 171 TABLE 190 JAPAN: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 172 TABLE 191 JAPAN: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 172 TABLE 192 JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 172 TABLE 193 JAPAN: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 173 TABLE 194 JAPAN: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 173 TABLE 195 JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 173 TABLE 196 INDIA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 174 TABLE 197 INDIA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 175 TABLE 198 INDIA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 175 TABLE 199 INDIA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 175 TABLE 200 INDIA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 176 TABLE 201 INDIA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 176 TABLE 202 REST OF ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 177 TABLE 203 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 177 TABLE 204 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 177 TABLE 205 REST OF ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 178 TABLE 206 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 178 TABLE 207 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 178 TABLE 208 LATIN AMERICA: KEY MACROINDICATORS 179 TABLE 209 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 210 LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 180 TABLE 211 LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 180 TABLE 212 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 180 TABLE 213 LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 181 TABLE 214 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 181 TABLE 215 LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 181 TABLE 216 BRAZIL: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 182 TABLE 217 BRAZIL: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 182 TABLE 218 BRAZIL: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 183 TABLE 219 BRAZIL: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 183 TABLE 220 BRAZIL: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 183 TABLE 221 BRAZIL: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 184 TABLE 222 REST OF LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 184 TABLE 223 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 184 TABLE 224 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 185 TABLE 225 REST OF LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 185 TABLE 226 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 227 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 228 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 187 TABLE 229 MIDDLE EAST & AFRICA: CRISPR MARKET, BY OFFERING, 2023–2030 (USD MILLION) 187 TABLE 230 MIDDLE EAST & AFRICA: CRISPR MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 187 TABLE 231 MIDDLE EAST & AFRICA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 188 TABLE 232 MIDDLE EAST & AFRICA: CRISPR MARKET, BY SERVICE, 2023–2030 (USD MILLION) 188 TABLE 233 MIDDLE EAST & AFRICA: CRISPR MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 188 TABLE 234 MIDDLE EAST & AFRICA: CRISPR SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 189 TABLE 235 STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, 2021−2025 191 TABLE 236 CRISPR MARKET: DEGREE OF COMPETITION 193 TABLE 237 CRISPR MARKET: REGION FOOTPRINT 197 TABLE 238 CRISPR MARKET: PRODUCT FOOTPRINT 197 TABLE 239 CRISPR MARKET: SERVICE FOOTPRINT 198 TABLE 240 CRISPR MARKET: APPLICATION FOOTPRINT 199 TABLE 241 CRISPR MARKET: DETAILED LIST OF KEY STARTUPS/SMES 201 TABLE 242 CRISPR MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES 202 TABLE 243 CRISPR MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 203 TABLE 244 CRISPR MARKET: DEALS, JANUARY 2021–MARCH 2025 204 TABLE 245 CRISPR MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025 205 TABLE 246 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 208 TABLE 247 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 209 TABLE 248 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025 211 TABLE 249 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025 211 TABLE 250 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 212 TABLE 251 MERCK KGAA: COMPANY OVERVIEW 214 TABLE 252 MERCK KGAA: PRODUCTS/SERVICES OFFERED 215 TABLE 253 MERCK KGAA: DEALS, JANUARY 2021–JANUARY 2025 216 TABLE 254 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 218 TABLE 255 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 219 TABLE 256 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–MARCH 2025 220 TABLE 257 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–MARCH 2025 221 TABLE 258 GENSCRIPT: COMPANY OVERVIEW 222 TABLE 259 GENSCRIPT: PRODUCTS/SERVICES OFFERED 223 TABLE 260 GENSCRIPT: PRODUCT/SERVICE APPROVALS/LAUNCHES, JANUARY 2021–MARCH 2025 225 TABLE 261 GENSCRIPT: DEALS, JANUARY 2021–MARCH 2025 225 TABLE 262 GENSCRIPT: EXPANSIONS, JANUARY 2021–MARCH 2025 226 TABLE 263 REVVITY: COMPANY OVERVIEW 227 TABLE 264 REVVITY: PRODUCTS/SERVICES OFFERED 228 TABLE 265 REVVITY: DEALS, JANUARY 2021–MARCH 2025 230 TABLE 266 LONZA: COMPANY OVERVIEW 231 TABLE 267 LONZA: PRODUCTS/SERVICES OFFERED 232 TABLE 268 LONZA: DEALS, JANUARY 2021–MARCH 2025 233 TABLE 269 DANAHER CORPORATION: COMPANY OVERVIEW 234 TABLE 270 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 235 TABLE 271 DANAHER CORPORATION: DEALS, JANUARY 2021–MARCH 2025 236 TABLE 272 TAKARA BIO INC.: COMPANY OVERVIEW 237 TABLE 273 TAKARA BIO INC.: PRODUCTS/SERVICES OFFERED 238 TABLE 274 TAKARA BIO INC.: DEALS, JANUARY 2021–MARCH 2025 239 TABLE 275 CREATIVE BIOGENE: COMPANY OVERVIEW 240 TABLE 276 CREATIVE BIOGENE: PRODUCTS/SERVICES OFFERED 240 TABLE 277 CREATIVE BIOGENE: PRODUCT/SERVICE APPROVALS/LAUNCHES, JANUARY 2021–MARCH 2025 241 TABLE 278 FUJIAN SUNYBIOTECH CO., LTD.: COMPANY OVERVIEW 242 TABLE 279 FUJIAN SUNYBIOTECH CO., LTD.: PRODUCTS/SERVICES OFFERED 242 TABLE 280 EDITCO: COMPANY OVERVIEW 243 TABLE 281 EDITCO: PRODUCTS/SERVICES OFFERED 243 TABLE 282 EDITCO: DEALS, JANUARY 2021–MARCH 2025 244 TABLE 283 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW 245 TABLE 284 CARIBOU BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 246 TABLE 285 CARIBOU BIOSCIENCES, INC.: DEALS, JANUARY 2021–MARCH 2025 246 TABLE 286 HERA BIOLABS: COMPANY OVERVIEW 247 TABLE 287 HERA BIOLABS: PRODUCTS/SERVICES OFFERED 247 TABLE 288 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 248 TABLE 289 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 248 TABLE 290 CELLECTA, INC.: COMPANY OVERVIEW 249 TABLE 291 CELLECTA, INC.: PRODUCTS/SERVICES OFFERED 249 TABLE 292 MAMMOTH BIOSCIENCES, INC.: COMPANY OVERVIEW 251 TABLE 293 APPLIED STEMCELL: COMPANY OVERVIEW 251 TABLE 294 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 252 TABLE 295 TOOLGEN, INC.: COMPANY OVERVIEW 253 TABLE 296 GENECOPOEIA, INC.: COMPANY OVERVIEW 254 TABLE 297 TWIST BIOSCIENCE: COMPANY OVERVIEW 255 TABLE 298 SYNTHEGO: COMPANY OVERVIEW 256 TABLE 299 EGENESIS: COMPANY OVERVIEW 257 TABLE 300 INSCRIPTA, INC.: COMPANY OVERVIEW 257 TABLE 301 PRECISION BIOSCIENCES: COMPANY OVERVIEW 258 FIGURE 1 CRISPR MARKET SEGMENTATION & REGIONAL SCOPE 25 FIGURE 2 CRISPR MARKET: RESEARCH DESIGN 29 FIGURE 3 CRISPR MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 31 FIGURE 4 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 32 FIGURE 5 CRISPR MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 33 FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024) 33 FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 35 FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 35 FIGURE 9 CRISPR MARKET: CAGR PROJECTIONS 37 FIGURE 10 DATA TRIANGULATION METHODOLOGY 39 FIGURE 11 CRISPR MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 42 FIGURE 12 CRISPR MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 43 FIGURE 13 CRISPR MARKET: GEOGRAPHICAL SNAPSHOT 43 FIGURE 14 RISING FOCUS ON CRISPR THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH 45 FIGURE 15 DRUG DISCOVERY & DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2024 46 FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 46 FIGURE 17 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47 FIGURE 18 TOP 10 LEADING CRISPR STARTUPS BASED ON INVESTMENTS RAISED IN 2024 50 FIGURE 19 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 57 FIGURE 20 CRISPR MARKET: SUPPLY CHAIN ANALYSIS 58 FIGURE 21 CRISPR MARKET: VALUE CHAIN ANALYSIS 59 FIGURE 22 CRISPR MARKET: ECOSYSTEM ANALYSIS 60 FIGURE 23 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS 62 FIGURE 24 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024) 73 FIGURE 25 AVERAGE SELLING PRICE OF KITS & REAGENTS, BY REGION, 2024 (USD) 76 FIGURE 26 PATENT APPLICATIONS FOR CRISPR (JANUARY 2014–DECEMBER 2024) 77 FIGURE 27 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 79 FIGURE 28 KEY BUYING CRITERIA OF END USERS FOR CRISPR PRODUCTS 80 FIGURE 29 KEY SELECTION CRITERIA OF END USERS FOR CRISPR SERVICES 80 FIGURE 30 CRISPR MARKET: INVESTMENT & FUNDING SCENARIO 81 FIGURE 31 IMPACT OF AI/GEN AI ON CRISPR MARKET 82 FIGURE 32 NORTH AMERICA: CRISPR MARKET SNAPSHOT 139 FIGURE 33 ASIA PACIFIC: CRISPR MARKET SNAPSHOT 166 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2020−2024 192 FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2024 193 FIGURE 36 CRISPR MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 195 FIGURE 37 CRISPR MARKET: COMPANY FOOTPRINT 196 FIGURE 38 CRISPR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 200 FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 206 FIGURE 40 EV/EBITDA OF KEY PLAYERS, 2024 206 FIGURE 41 CRISPR MARKET: BRAND/PRODUCT COMPARISON 207 FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 209 FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2024) 215 FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 219 FIGURE 45 GENSCRIPT: COMPANY SNAPSHOT (2023) 223 FIGURE 46 REVVITY: COMPANY SNAPSHOT (2024) 228 FIGURE 47 LONZA: COMPANY SNAPSHOT (2024) 232 FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 235 FIGURE 49 TAKARA BIO INC.: COMPANY SNAPSHOT (2023) 238 FIGURE 50 CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024) 245

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們